ASPEN PARK PHARMACEUTICALS INC has a total of 33 patent applications. It decreased the IP activity by 75.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals are BARTELS STEPHEN P, NOVO NORDISK FEMCARE AG and GRANDIS BIOTECH GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | China | 4 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Australia | 3 | |
#5 | Israel | 3 | |
#6 | Republic of Korea | 3 | |
#7 | Mexico | 3 | |
#8 | WIPO (World Intellectual Property Organization) | 3 | |
#9 | Canada | 1 | |
#10 | Hungary | 1 | |
#11 | Russian Federation | 1 | |
#12 | Ukraine | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Fisch Harry | 20 |
#2 | Steiner Mitchell | 19 |
#3 | Phelps Kenneth V | 7 |
#4 | Gold Lynn | 7 |
#5 | Stevens Ruth E | 7 |
#6 | Barnette K Gary | 7 |
#7 | Mitchell Steiner | 2 |
#8 | Harry Fisch | 2 |
#9 | Ruth E Stevens | 1 |
#10 | Lynn Gold | 1 |
Publication | Filing date | Title |
---|---|---|
US2019046465A1 | Individually-packaged wipes for enhancing sexual intercourse | |
EP3452016A1 | Delayed release oral tamsulosin hydrochloride | |
US2019054044A1 | Oral dosage form of both clomiphene isomers and method of using same to treat secondary hypogonadism and minimize drug side effects in men | |
CN111346076A | Treatment of androgen deprivation therapy induced hot flashes and bone loss using cis-clomiphene |